Sequential Versus Alternating Administration of Cisplatin/Etoposide and Topotecan as First-Line Treatment in Extensive-Stage Small-Cell Lung Cancer: Preliminary Results of a Phase III Trial of the Hellenic Oncology Research Group

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Nonparametric Estimation from Incomplete Observations

1958 • 37,219 citations

Cancer: Principles and Practice of Oncology.

1991 • 8,402 citations

Reporting results of cancer treatment

1981 • 7,916 citations

Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

2002 • 1,346 citations

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

1999 • 909 citations

Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

2006 • 654 citations

Rationale for the use of alternating non-cross-resistant chemotherapy.

1982 • 545 citations

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.

1992 • 532 citations

Cancer: Principles and Practice of Oncology

1982 • 513 citations

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

1997 • 474 citations

Topotecan Versus Observation After Cisplatin Plus Etoposide in Extensive-Stage Small-Cell Lung Cancer: E7593—A Phase III Trial of the Eastern Cooperative Oncology Group

2001 • 289 citations

Superiority of Alternating Non-Cross-Resistant Chemotherapy in Extensive Small Cell Lung Cancer

1987 • 227 citations

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.

1996 • 206 citations

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.

1996 • 132 citations

Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation

2002 • 130 citations

Chemotherapy for small cell lung cancer

2003 • 119 citations

Maintenance chemotherapy for small cell lung cancer: a critical review of the literature

1998 • 94 citations

Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients

1998 • 79 citations

The significance of the sequence of administration of topotecan and etoposide

1996 • 72 citations

126 Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study

1997 • 63 citations

Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC)

2005 • 35 citations

Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: An EORTC phase iii trial

1996 • 34 citations

Single agent oral topotecan (OT) as first-line treatment for patients (pts) with extensive disease (ED) small cell lung cancer (SCLC) ineligible for standard therapy: A phase II study

2000 • 33 citations

Topotecan in the First-Line Treatment of Small Cell Lung Cancer

2004 • 29 citations

Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive‐stage small cell lung carcinoma

2003 • 26 citations

Cisplatin–etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC)

2002 • 21 citations

Topotecan (Hycamtin™) in small cell lung cancer (SCLC) after failure of first line therapy: Multicentre phase II study

1997 • 16 citations

Sequential administration of cisplatin–etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study

2002 • 15 citations